저분자 CMO/CDMO 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Small Molecule CMO/CDMO Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

US $ 4,995 ￦ 7,227,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,555,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 12,291,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

전 세계 저분자 CMO/CDMO 시장 규모는 2025년에 792억 8,000만 달러로 2025-2032년 예측 기간 동안 5.3%의 CAGR로 확대되어 2032년에는 1,141억 7,000만 달러에 달할 것으로 예상됩니다.

저분자 CMO/CDMO 시장에는 저분자 의약품의 위탁 생산 및 시장 개척 위탁 서비스가 광범위하게 포함됩니다. 이러한 서비스는 제약 및 생명공학 기업을 위해 설계되었으며, 의약품 개발, 제형화, 제조 및 포장을 위한 엔드-투-엔드 솔루션을 제공합니다. 이 시장은 대형 제약사, 신생 바이오테크놀러지 기업, 제네릭 제약사 등 다양한 부문에 서비스를 제공하고 있습니다. 성장의 원동력은 아웃소싱 트렌드, 비용 효율성 향상, 의약품 제형 및 제조에 대한 전문 지식에 대한 수요 증가입니다.

세계 저분자 CMO/CDMO 시장을 이끄는 주요 요인은 다음과 같습니다. 비용 절감과 높은 업무 효율성으로 인해 의약품 제조 공정의 아웃소싱에 대한 수요가 증가하고 있는 것이 시장 성장의 원동력이 되고 있습니다. 또한, 의약품 승인 건수의 증가와 저분자 의약품의 복잡성 증가로 인해 제약기업들은 전문 제조 파트너를 찾고 있습니다. 연속 제조 및 고역가 원료의약품(HPAPI) 제조와 같은 첨단 제조 기술의 통합은 시장 확대를 더욱 촉진하고 있습니다. 또한, 규제 대응 및 GMP(Good Manufacturing Practice) 전문 지식의 필요성이 전문 CMO/CDMO와의 제휴를 촉진하고 있습니다.

암 및 중추신경계(CNS) 질환과 같은 고부가가치 및 틈새 치료 분야에 대한 수요 증가로 인해 시장은 큰 기회를 창출하고 있습니다. 고활성 의약품 성분(HPAPI)과 나노 분쇄 및 분무건조와 같은 특수 제형 기술 분야의 역량 확대는 유리한 성장 잠재력을 제공합니다. 신흥 시장, 특히 아시아태평양은 낮은 운영 비용과 양호한 규제 환경으로 인해 CMO/CDMO에 큰 기회를 제공하고 있습니다. 또한, 위탁 제조 공정의 디지털 혁신과 자동화의 발전은 효율성과 확장성을 향상시켜 시장 성장을 더욱 촉진하고 있습니다.

세계의 저분자 CMO/CDMO 시장에 대해 조사했으며, 제품별, 서비스별, 기업 규모별, 운영 규모별, 지역별 동향, 시장 진출 기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위와 정의
• 시장 역학
• 거시경제 요인
• COVID-19의 영향 분석
• 예측요인 - 관련성과 영향

제3장 부가가치 인사이트

제4장 세계의 저분자 CMO/CDMO 시장 전망

• 주요 하이라이트
• 시장 규모(10억 달러) 분석과 예측
• 세계의 저분자 CMO/CDMO 시장 전망 : 제품별
• 세계의 저분자 CMO/CDMO 시장 전망 : 서비스별
• 세계의 저분자 CMO/CDMO 시장 전망 : 기업 규모별
• 세계의 저분자 CMO/CDMO 시장 전망 : 운영 규모별

제5장 세계의 저분자 CMO/CDMO 시장 전망 : 지역별

• 주요 하이라이트
• 과거 시장 규모(10억 달러) 분석, 지역별, 2019-2024년
• 현재 시장 규모(10억 달러) 분석과 예측, 지역별, 2025-2032년
• 시장 매력 분석 : 지역별

제6장 북미의 저분자 CMO/CDMO 시장 전망

제7장 유럽의 저분자 CMO/CDMO 시장 전망

제8장 동아시아의 저분자 CMO/CDMO 시장 전망

제9장 남아시아 및 오세아니아의 저분자 CMO/CDMO 시장 전망

제10장 라틴아메리카의 저분자 CMO/CDMO 시장 전망

제11장 중동 및 아프리카의 저분자 CMO/CDMO 시장 전망

제12장 경쟁 구도

• 시장 점유율 분석, 2024년
• 시장 구조
• 기업 개요(상세 - 개요, 재무, 전략, 최근 동향)
  • Lonza
  • Pfizer CentreOne(Pfizer Inc.)
  • Piramal Pharma Solutions
  • Wuxi App Tec
  • Patheon(Thermo Fisher Scientific Inc.)
  • Ajinomoto Bio-Pharma Solutions
  • Siegfried Holding AG
  • Eurofins Scientific
  • Aurigene Pharmaceutical Services Ltd.
  • Asymchema
  • PCI Pharma Services
  • Almac Group
  • Labcorp Drug Development
  • Sumitomo Chemical Co., Ltd.
  • ICROM
  • AGC Inc.
  • FUJIFILM Corporation
  • CMIC HOLDINGS Co., LTD.
  • Evonik
  • Terumo Pharmaceutical Solutions

제13장 부록

ksm

영문 목차

영문목차

Persistence Market Research has recently published an extensive report on the global Small Molecule CMO/CDMO Market. This report offers a comprehensive analysis of the key market dynamics, including drivers, trends, opportunities, and challenges, providing deep insights into the market structure.

Key Insights:

• Small Molecule CMO/CDMO Market Size (2025E): USD 79.28 Bn
• Projected Market Value (2032F): USD 114.17 Bn
• Global Market Growth Rate (CAGR 2025 to 2032): 5.3%

Small Molecule CMO/CDMO Market - Report Scope:

The Small Molecule CMO/CDMO Market encompasses a broad range of contract manufacturing and contract development services for pharmaceutical small molecules. These services are designed to cater to pharmaceutical and biotechnology companies, providing end-to-end solutions for drug development, formulation, production, and packaging. The market serves various segments, including large pharmaceutical firms, emerging biotech companies, and generic drug manufacturers. Growth is driven by increasing outsourcing trends, cost-efficiency, and the rising demand for specialized expertise in drug formulation and production.

Market Growth Drivers:

Several key factors are driving the global Small Molecule CMO/CDMO Market. The rising demand for outsourcing pharmaceutical manufacturing processes due to cost advantages and operational efficiencies is fueling market growth. Additionally, the increasing number of drug approvals and the growing complexity of small molecule drugs have led pharmaceutical companies to seek specialized manufacturing partners. The integration of advanced manufacturing technologies such as continuous manufacturing and high-potency API (HPAPI) production is further supporting market expansion. Furthermore, regulatory compliance and the need for expertise in Good Manufacturing Practices (GMP) are encouraging companies to collaborate with specialized CMO/CDMOs.

Market Restraints:

Despite promising growth prospects, the Small Molecule CMO/CDMO Market faces challenges related to stringent regulatory requirements and intellectual property concerns. The complex approval processes for contract manufacturers, including compliance with the U.S. FDA, EMA, and other regulatory agencies, can delay production timelines. Additionally, pharmaceutical companies often face concerns about the security of proprietary formulations and technologies when outsourcing to third parties. Market growth can also be hindered by capacity constraints at contract manufacturing facilities and the high costs associated with advanced technological capabilities.

Market Opportunities:

The market presents significant opportunities driven by the increasing demand for high-value and niche therapeutic applications, including oncology and central nervous system (CNS) disorders. The expansion of capabilities in high-potency active pharmaceutical ingredients (HPAPIs) and specialized formulation techniques, such as nano-milling and spray drying, provides lucrative growth potential. Emerging markets, particularly in Asia-Pacific, present significant opportunities for CMO/CDMOs due to lower operational costs and favorable regulatory environments. Additionally, advancements in digital transformation and automation in contract manufacturing processes are improving efficiency and scalability, further driving market growth.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Small Molecule CMO/CDMO Market globally?
• Which contract manufacturing and development services are in high demand across pharmaceutical companies?
• How are technological advancements influencing the competitive landscape of the Small Molecule CMO/CDMO Market?
• Who are the key players in the Small Molecule CMO/CDMO Market, and what strategies are they employing to stay competitive?
• What are the emerging trends and future prospects in the global Small Molecule CMO/CDMO Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Small Molecule CMO/CDMO Market, including Lonza Group, Catalent Inc., and WuXi AppTec, focus on innovation, capacity expansion, and strategic collaborations to gain a competitive edge. These companies invest in R&D to enhance contract development and manufacturing capabilities while expanding their service portfolios. Collaborations with pharmaceutical firms, biotech startups, and government agencies facilitate market access and support long-term growth. Emphasis on regulatory compliance, high-quality manufacturing standards, and robust marketing strategies fosters market expansion and strengthens brand reputation in the evolving Small Molecule CMO/CDMO Market landscape.

Key Companies Profiled:

• Lonza
• Pfizer CentreOne (Pfizer Inc.)
• Piramal Pharma Solutions
• Wuxi App Tec
• Patheon (Thermo Fisher Scientific Inc.)
• Ajinomoto Bio-Pharma Solutions
• Siegfried Holding AG
• Eurofins Scientific
• Aurigene Pharmaceutical Services Ltd.
• Asymchema
• PCI Pharma Services
• Almac Group
• Labcorp Drug Development
• Sumitomo Chemical Co., Ltd.
• ICROM
• AGC Inc.
• FUJIFILM Corporation
• CMIC HOLDINGS Co., LTD.
• Evonik
• Terumo Pharmaceutical Solutions (TPS)

Small Molecule CMO/CDMO Market Segmentation

By Product

• Standard API
• HP API

By Service

• Process Development
• Analytical Method Development
• GMP Manufacturing Service
• Scale-up and Tech Transfer
• Regulatory Assistance
• Fill-finish Services

By Company Size

• Small
• Mid-sized
• Large

By Scale of Operation

• Clinical
• Commercial

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Middle East and Africa
• Latin America

Table of Contents

1. Executive Summary

• 1.1. Global Small Molecule CMO/CDMO Market Outlook
• 1.2. Global Small Molecule CMO/CDMO Market Outlook: Services
• 1.3. Introduction/Key Findings
• 1.4. Historical Market Size (US$ Bn) and Analysis, By Services, 2019 - 2024
• 1.5. Current Market Size (US$ Bn) and Analysis and Forecast, By Services, 2025 - 2032
• 1.6. Key Market Trends
• 1.7. Future Market Projections
• 1.8. Premium Market Insights
• 1.9. Industry Developments and Key Market Events
• 1.10. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Product Adoption Analysis
• 3.3. Value Chain Analysis
• 3.4. Key Deals and Mergers
• 3.5. PESTLE Analysis
• 3.6. Porter's Five Force Analysis

4. Global Small Molecule CMO/CDMO Market Outlook:

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2024
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025 - 2032
• 4.3. Global Small Molecule CMO/CDMO Market Outlook: Product
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product, 2019 - 2024
  • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
    • 4.3.3.1. Standard API
    • 4.3.3.2. HP API
  • 4.3.4. Market Attractiveness Analysis: Product
• 4.4. Global Small Molecule CMO/CDMO Market Outlook: Service
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Service, 2019 - 2024
  • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
    • 4.4.3.1. Process Development
    • 4.4.3.2. Analytical Method Development
    • 4.4.3.3. GMP Manufacturing Service
    • 4.4.3.4. Scale-up and Tech Transfer
    • 4.4.3.5. Regulatory Assistance
    • 4.4.3.6. Fill-Finish Services
  • 4.4.4. Market Attractiveness Analysis: Service
• 4.5. Global Small Molecule CMO/CDMO Market Outlook: Company Size
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Company Size, 2019 - 2024
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
    • 4.5.3.1. Small
    • 4.5.3.2. Mid-sized
    • 4.5.3.3. Large
  • 4.5.4. Market Attractiveness Analysis: Company Size
• 4.6. Global Small Molecule CMO/CDMO Market Outlook: Scale of Operation
  • 4.6.1. Introduction / Key Findings
  • 4.6.2. Historical Market Size (US$ Bn) Analysis, By Scale of Operation, 2019 - 2024
  • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
    • 4.6.3.1. Clinical
    • 4.6.3.2. Commercial
  • 4.6.4. Market Attractiveness Analysis: Scale of Operation

5. Global Small Molecule CMO/CDMO Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2024
• 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025 - 2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Small Molecule CMO/CDMO Market Outlook:

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  • 6.2.1. By Country
  • 6.2.2. By Product
  • 6.2.3. By Service
  • 6.2.4. By Company Size
  • 6.2.5. By Scale of Operation
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
  • 6.4.1. Standard API
  • 6.4.2. HP API
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
  • 6.5.1. Process Development
  • 6.5.2. Analytical Method Development
  • 6.5.3. GMP Manufacturing Service
  • 6.5.4. Scale-up and Tech Transfer
  • 6.5.5. Regulatory Assistance
  • 6.5.6. Fill-Finish Services
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
  • 6.6.1. Small
  • 6.6.2. Mid-sized
  • 6.6.3. Large
• 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
  • 6.7.1. Clinical
  • 6.7.2. Commercial
• 6.8. Market Attractiveness Analysis

7. Europe Small Molecule CMO/CDMO Market Outlook:

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  • 7.2.1. By Country
  • 7.2.2. By Product
  • 7.2.3. By Service
  • 7.2.4. By Company Size
  • 7.2.5. By Scale of Operation
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
  • 7.4.1. Standard API
  • 7.4.2. HP API
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
  • 7.5.1. Process Development
  • 7.5.2. Analytical Method Development
  • 7.5.3. GMP Manufacturing Service
  • 7.5.4. Scale-up and Tech Transfer
  • 7.5.5. Regulatory Assistance
  • 7.5.6. Fill-Finish Services
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
  • 7.6.1. Small
  • 7.6.2. Mid-sized
  • 7.6.3. Large
• 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
  • 7.7.1. Clinical
  • 7.7.2. Commercial
• 7.8. Market Attractiveness Analysis

8. East Asia Small Molecule CMO/CDMO Market Outlook:

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  • 8.2.1. By Country
  • 8.2.2. By Product
  • 8.2.3. By Service
  • 8.2.4. By Company Size
  • 8.2.5. By Scale of Operation
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
  • 8.4.1. Standard API
  • 8.4.2. HP API
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
  • 8.5.1. Process Development
  • 8.5.2. Analytical Method Development
  • 8.5.3. GMP Manufacturing Service
  • 8.5.4. Scale-up and Tech Transfer
  • 8.5.5. Regulatory Assistance
  • 8.5.6. Fill-Finish Services
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
  • 8.6.1. Small
  • 8.6.2. Mid-sized
  • 8.6.3. Large
• 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
  • 8.7.1. Clinical
  • 8.7.2. Commercial
• 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Small Molecule CMO/CDMO Market Outlook:

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  • 9.2.1. By Country
  • 9.2.2. By Product
  • 9.2.3. By Service
  • 9.2.4. By Company Size
  • 9.2.5. By Scale of Operation
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
  • 9.4.1. Standard API
  • 9.4.2. HP API
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
  • 9.5.1. Process Development
  • 9.5.2. Analytical Method Development
  • 9.5.3. GMP Manufacturing Service
  • 9.5.4. Scale-up and Tech Transfer
  • 9.5.5. Regulatory Assistance
  • 9.5.6. Fill-Finish Services
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
  • 9.6.1. Small
  • 9.6.2. Mid-sized
  • 9.6.3. Large
• 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
  • 9.7.1. Clinical
  • 9.7.2. Commercial
• 9.8. Market Attractiveness Analysis

10. Latin America Small Molecule CMO/CDMO Market Outlook:

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  • 10.2.1. By Country
  • 10.2.2. By Product
  • 10.2.3. By Service
  • 10.2.4. By Company Size
  • 10.2.5. By Scale of Operation
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
  • 10.4.1. Standard API
  • 10.4.2. HP API
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
  • 10.5.1. Process Development
  • 10.5.2. Analytical Method Development
  • 10.5.3. GMP Manufacturing Service
  • 10.5.4. Scale-up and Tech Transfer
  • 10.5.5. Regulatory Assistance
  • 10.5.6. Fill-Finish Services
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
  • 10.6.1. Small
  • 10.6.2. Mid-sized
  • 10.6.3. Large
• 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
  • 10.7.1. Clinical
  • 10.7.2. Commercial
• 10.8. Market Attractiveness Analysis

11. Middle East & Africa Small Molecule CMO/CDMO Market Outlook:

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  • 11.2.1. By Country
  • 11.2.2. By Product
  • 11.2.3. By Service
  • 11.2.4. By Company Size
  • 11.2.5. By Scale of Operation
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
  • 11.4.1. Standard API
  • 11.4.2. HP API
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
  • 11.5.1. Process Development
  • 11.5.2. Analytical Method Development
  • 11.5.3. GMP Manufacturing Service
  • 11.5.4. Scale-up and Tech Transfer
  • 11.5.5. Regulatory Assistance
  • 11.5.6. Fill-Finish Services
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
  • 11.6.1. Small
  • 11.6.2. Mid-sized
  • 11.6.3. Large
• 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
  • 11.7.1. Clinical
  • 11.7.2. Commercial
• 11.8. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Lonza
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Pfizer CentreOne (Pfizer Inc.)
  • 12.3.3. Piramal Pharma Solutions
  • 12.3.4. Wuxi App Tec
  • 12.3.5. Patheon (Thermo Fisher Scientific Inc.)
  • 12.3.6. Ajinomoto Bio-Pharma Solutions
  • 12.3.7. Siegfried Holding AG
  • 12.3.8. Eurofins Scientific
  • 12.3.9. Aurigene Pharmaceutical Services Ltd.
  • 12.3.10. Asymchema
  • 12.3.11. PCI Pharma Services
  • 12.3.12. Almac Group
  • 12.3.13. Labcorp Drug Development
  • 12.3.14. Sumitomo Chemical Co., Ltd.
  • 12.3.15. ICROM
  • 12.3.16. AGC Inc.
  • 12.3.17. FUJIFILM Corporation
  • 12.3.18. CMIC HOLDINGS Co., LTD.
  • 12.3.19. Evonik
  • 12.3.20. Terumo Pharmaceutical Solutions (TPS)

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료